trending Market Intelligence /marketintelligence/en/news-insights/trending/FWzLM2tY7JgU2FXzpTdv4g2 content esgSubNav
In This List

HedgePath Pharmaceuticals changes name to Inhibitor Therapeutics

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


HedgePath Pharmaceuticals changes name to Inhibitor Therapeutics

HedgePath Pharmaceuticals Inc. has changed its name to Inhibitor Therapeutics Inc. The company is narrowing its focus on commercializing therapeutics that inhibit the progression of cancerous and noncancerous proliferation disorders.

The Tampa, Fla.-based biopharmaceutical company will change its ticker symbol to INTI from HPPI to reflect the rebranding. It will also unveil a new website focusing on its development of a U.S. Food and Drug Administration-approved formulation called Suba-Itraconazole for treating systematic fungal infections.

The company plans to hold discussions in 2020 with the FDA to advance its phase 2b clinical program to study Suba-Itraconazole in patients with late-stage lung cancer, it said in a press release.